Evidence map›Paper›PMID 15517127›Full record

ArticleDer Internist2004

[New therapeutic approaches to COPD].

M Pfeifer

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Internist, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

M PfeiferKlinik Donaustauf, Universität Regensburg. michael.pfeifer@klinik.uni-regensburg.de
Klinik Donaustauf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Classification of severity of the disease is the basis of the therapeutic concept for chronic obstructive lung disease (COPD). Besides pharmacological treatment, preventive measures and rehabilitation with training are the main parts of COPD therapy. Weaning patients of cigarette smoking is of utmost importance in every stage for the course of the disease. Inhalative short acting bronchodilators on demand are the basis of treatment in all stages as well as long acting bronchodilators from stage II on as continuous medication. Theophyllines are of additional importance in higher degrees of the disease. Inhalative steroids are indicated in severe stages III or higher, systemic steroids only during exacerbations as short course therapy. Oxygen long time treatment, intermittent non-invasive ventilation, and operations in some cases are additional therapies.

Indexed as

Administration, InhalationBronchodilator AgentsHumansIntermittent Positive-Pressure VentilationOxygen Inhalation TherapyPractice Guidelines as TopicPractice Patterns, Physicians'Pulmonary Disease, Chronic ObstructiveSmoking CessationSteroidsTreatment OutcomeBronchodilator AgentsSteroids

Identifiers

PMID15517127
OpenAlexW2598180742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.